These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34656144)

  • 21. Targeted Therapies for Hereditary Peripheral Neuropathies: Systematic Review and Steps Towards a 'treatabolome'.
    Jennings MJ; Lochmüller A; Atalaia A; Horvath R
    J Neuromuscul Dis; 2021; 8(3):383-400. PubMed ID: 32773395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients.
    Mannil M; Solari A; Leha A; Pelayo-Negro AL; Berciano J; Schlotter-Weigel B; Walter MC; Rautenstrauss B; Schnizer TJ; Schenone A; Seeman P; Kadian C; Schreiber O; Angarita NG; Fabrizi GM; Gemignani F; Padua L; Santoro L; Quattrone A; Vita G; Calabrese D; ; Young P; Laurà M; Haberlová J; Mazanec R; Paulus W; Beissbarth T; Shy ME; Reilly MM; Pareyson D; Sereda MW
    Neuromuscul Disord; 2014 Nov; 24(11):1003-17. PubMed ID: 25085517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients.
    Sahenk Z; Nagaraja HN; McCracken BS; King WM; Freimer ML; Cedarbaum JM; Mendell JR
    Neurology; 2005 Sep; 65(5):681-9. PubMed ID: 16157899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative assessment of sciatic nerve changes in Charcot-Marie-Tooth type 1A patients using magnetic resonance neurography.
    Fortanier E; Ogier AC; Delmont E; Lefebvre MN; Viout P; Guye M; Bendahan D; Attarian S
    Eur J Neurol; 2020 Aug; 27(8):1382-1389. PubMed ID: 32391944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Skin Biopsy Findings in Patients With CMT1A: Baseline Data From the CLN-PXT3003-01 Study Provide New Insights Into the Pathophysiology of the Disorder.
    Duchesne M; Danigo A; Richard L; Vallat JM; Attarian S; Gonnaud PM; Lacour A; Péréon Y; Stojkovic T; Nave KA; Bertrand V; Nabirotchkin S; Cohen D; Demiot C; Magy L
    J Neuropathol Exp Neurol; 2018 Apr; 77(4):274-281. PubMed ID: 29408953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A.
    Attarian S; Young P; Brannagan TH; Adams D; Van Damme P; Thomas FP; Casanovas C; Kafaie J; Tard C; Walter MC; Péréon Y; Walk D; Stino A; de Visser M; Verhamme C; Amato A; Carter G; Magy L; Statland JM; Felice K
    Orphanet J Rare Dis; 2024 Apr; 19(1):142. PubMed ID: 38561848
    [No Abstract]   [Full Text] [Related]  

  • 27. A Rasch Analysis of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) in a Cohort of Charcot-Marie-Tooth Type 1A Patients.
    Wang W; Guedj M; Bertrand V; Foucquier J; Jouve E; Commenges D; Proust-Lima C; Murphy NP; Blin O; Magy L; Cohen D; Attarian S
    PLoS One; 2017; 12(1):e0169878. PubMed ID: 28095456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Employment status of patients with Charcot-Marie-Tooth type 1A.
    Bjelica B; Brankovic M; Bozovic I; Palibrk A; Kacar A; Rakocevic-Stojanovic V
    Acta Neurol Belg; 2022 Jun; 122(3):641-646. PubMed ID: 33491123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Motor performance deterioration accelerates after 50 years of age in Charcot-Marie-Tooth type 1A patients.
    Tozza S; Bruzzese D; Pisciotta C; Iodice R; Esposito M; Dubbioso R; Ruggiero L; Topa A; Spina E; Santoro L; Manganelli F
    Eur J Neurol; 2018 Feb; 25(2):301-306. PubMed ID: 29053907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Poor tolerability of high dose ascorbic acid in a population of genetically confirmed adult Charcot-Marie-Tooth 1A patients.
    Toth C
    Acta Neurol Scand; 2009 Aug; 120(2):134-8. PubMed ID: 19154534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Charcot‑Marie‑Tooth type 1A drug therapies: role of adenylyl cyclase activity and G‑protein coupled receptors in disease pathomechanism.
    Kiepura AJ; Kochański A
    Acta Neurobiol Exp (Wars); 2018; 78(3):198-209. PubMed ID: 30295677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of real-time quantitative PCR compare to repeat PCR for the diagnosis of Charcot-Marie-Tooth Type 1A and hereditary neuropathy with liability to pressure palsies.
    Choi JR; Lee WH; Sunwoo IN; Lee EK; Lee CH; Lim JB
    Yonsei Med J; 2005 Jun; 46(3):347-52. PubMed ID: 15988805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombination hot spot in a 3.2-kb region of the Charcot-Marie-Tooth type 1A repeat sequences: new tools for molecular diagnosis of hereditary neuropathy with liability to pressure palsies and of Charcot-Marie-Tooth type 1A. French CMT Collaborative Research Group.
    Lopes J; LeGuern E; Gouider R; Tardieu S; Abbas N; Birouk N; Gugenheim M; Bouche P; Agid Y; Brice A
    Am J Hum Genet; 1996 Jun; 58(6):1223-30. PubMed ID: 8651299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome measures in the clinical evaluation of ambulatory Charcot-Marie-Tooth 1A subjects.
    Mori L; Prada V; Signori A; Pareyson D; Piscosquito G; Padua L; Pazzaglia C; Fabrizi GM; Smania N; Picelli A; Schenone A;
    Eur J Phys Rehabil Med; 2019 Feb; 55(1):47-55. PubMed ID: 29898585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel histone deacetylase 6 inhibitor improves myelination of Schwann cells in a model of Charcot-Marie-Tooth disease type 1A.
    Ha N; Choi YI; Jung N; Song JY; Bae DK; Kim MC; Lee YJ; Song H; Kwak G; Jeong S; Park S; Nam SH; Jung SC; Choi BO
    Br J Pharmacol; 2020 Nov; 177(22):5096-5113. PubMed ID: 33460073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene therapy and other novel treatment approaches for Charcot-Marie-Tooth disease.
    Pisciotta C; Pareyson D
    Neuromuscul Disord; 2023 Aug; 33(8):627-635. PubMed ID: 37455204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral myelin protein 22 gene duplication with atypical presentations: a new example of the wide spectrum of Charcot-Marie-Tooth 1A disease.
    Mathis S; Corcia P; Tazir M; Camu W; Magdelaine C; Latour P; Biberon J; Guennoc AM; Richard L; Magy L; Funalot B; Vallat JM
    Neuromuscul Disord; 2014 Jun; 24(6):524-8. PubMed ID: 24792522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study.
    Morrow JM; Sinclair CD; Fischmann A; Machado PM; Reilly MM; Yousry TA; Thornton JS; Hanna MG
    Lancet Neurol; 2016 Jan; 15(1):65-77. PubMed ID: 26549782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paternal gender specificity and mild phenotypes in Charcot-Marie-Tooth type 1A patients with de novo 17p12 rearrangements.
    Lee AJ; Nam DE; Choi YJ; Noh SW; Nam SH; Lee HJ; Kim SJ; Song GJ; Choi BO; Chung KW
    Mol Genet Genomic Med; 2020 Sep; 8(9):e1380. PubMed ID: 32648354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.